Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation.
COVID-19
molnupiravir
sotrovimab
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
26
07
2022
accepted:
04
10
2022
entrez:
2
11
2022
pubmed:
3
11
2022
medline:
3
11
2022
Statut:
epublish
Résumé
COVID-19 medicines delivery units (CMDU) were established in late December 2021 to deliver early antiviral therapy to patients classified as at risk with the aim of preventing hospitalization. We performed a service evaluation at 4 CMDUs in England. We assessed demographics and triage outcomes of CMDU referral, uptake of antiviral therapy, and the rate of subsequent hospitalizations within 2 weeks of CMDU referral. Over a 3-week period, 4788 patients were referred and 3989 were ultimately assessed by a CMDU. Overall, 832 of the patients referred (17%) were judged eligible for treatment and 628 (13%) were ultimately prescribed an antiviral agent. The overall rate of admission within 14 days was 1%. Patients who were admitted were significantly older than those who did not require hospitalization. Of patients prescribed molnupiravir and sotrovimab, 1.8% and 3.2%, respectively, were admitted. There was a high volume of referrals to CMDU service during the initial surge of the Omicron wave in the United Kingdom. A minority of patients were judged to be eligible for therapy. In a highly vaccinated population, the overall hospitalization rate was low.
Sections du résumé
Background
UNASSIGNED
COVID-19 medicines delivery units (CMDU) were established in late December 2021 to deliver early antiviral therapy to patients classified as at risk with the aim of preventing hospitalization.
Methods
UNASSIGNED
We performed a service evaluation at 4 CMDUs in England. We assessed demographics and triage outcomes of CMDU referral, uptake of antiviral therapy, and the rate of subsequent hospitalizations within 2 weeks of CMDU referral.
Results
UNASSIGNED
Over a 3-week period, 4788 patients were referred and 3989 were ultimately assessed by a CMDU. Overall, 832 of the patients referred (17%) were judged eligible for treatment and 628 (13%) were ultimately prescribed an antiviral agent. The overall rate of admission within 14 days was 1%. Patients who were admitted were significantly older than those who did not require hospitalization. Of patients prescribed molnupiravir and sotrovimab, 1.8% and 3.2%, respectively, were admitted.
Conclusions
UNASSIGNED
There was a high volume of referrals to CMDU service during the initial surge of the Omicron wave in the United Kingdom. A minority of patients were judged to be eligible for therapy. In a highly vaccinated population, the overall hospitalization rate was low.
Identifiants
pubmed: 36320201
doi: 10.1093/ofid/ofac527
pii: ofac527
pmc: PMC9605703
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac527Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors: No reported conflicts of interest.
Références
Lancet. 2022 Feb 26;399(10327):800-802
pubmed: 35065703
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
Br J Gen Pract. 2021 Dec 31;72(714):e51-e62
pubmed: 34750106
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
BMC Infect Dis. 2022 Mar 29;22(1):311
pubmed: 35351016